FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01133990
• Other study ID #: E7820-701
• Secondary ID: 2009-016015-37
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: March 4, 2010
• Est. completion date: February 18, 2011

Study information

• Verified date: July 2012
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.

The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.

Description:

The primary purpose for Phase 1b: to determine the maximum tolerated dose (MTD) of E7820 recommended for Phase 2 when administered in combination with the FOLFIRI regimen (irinotecan, leucovorin, and 5-fluorouracil [5-FU]) in participants with locally advanced or metastatic colorectal cancer (mCRC) who have failed first-line therapy. Phase 2: to evaluate the safety and tolerability of E7820 administered in combination with the FOLFIRI regimen, compared with FOLFIRI alone and FOLFIRI plus bevacizumab, in patients with locally advanced or mCRC who have failed first-line therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: February 18, 2011
• Est. primary completion date: February 18, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients may be entered in the study only if they meet all of the following criteria:

1. Male or female patient greater than or equal to 18 years of age;

2. Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma;

3. Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line bevacizumab is allowed). Patients randomized to the Phase Ib portion can have up to 3 total prior regimens (including adjuvant therapy in addition to treatment for advanced disease);

4. At least 1 site of measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria;

5. Life expectancy of > 3 months;

6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1;

7. Patients must have adequate renal function as evidenced by serum creatinine <2 mg/dL and creatinine clearance >50 mL/minute per the Cockcroft and Gault formula;

8. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >1.5 x 109/L, platelets >100 x 109/L, hemoglobin >9.0 g/dL (a hemoglobin <9.0 g/dL at Screening is acceptable if it is corrected to >9 g/dL by growth factor or transfusion prior to first dose);

9. Patients must have adequate liver function as evidenced by bilirubin <1.5 times the upper limit of the normal range (ULN), and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <3 X ULN (in the case of liver metastases, <5 X ULN). If there are bone metastases, liver-specific alkaline phosphatase may be separated from the total and used to assess liver function instead of total alkaline phosphatase;

10. Blood pressure must be well-controlled (<140/90 mmHg at screening) with or without antihypertensive medication. Patients must have no history of hypertensive crisis or hypertensive encephalopathy;

11. Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment;

12. Females of childbearing potential must have a negative serum pregnancy test;

13. Females may not be breastfeeding; and

14. Ability to understand and willingness to sign a written consent.

Exclusion Criteria:

Patients will not be entered in the study for any of the following reasons:

1. Received chemotherapy, targeted therapy, radiotherapy, surgery, immunotherapy, or treatment in another clinical study within the 30 days prior to commencing study treatment or have not recovered from side effects of all treatment-related toxicities to Grade <1, except for peripheral neuropathy (Grade 1 and Grade 2 are permitted) and alopecia;

2. Previously received irinotecan or irinotecan derivatives;

3. Previously received anti-alpha 2 integrin therapy;

4. History of other malignancies except: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for >5 years;

5. Presence of brain metastases, unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization;

6. Are currently receiving any other anticancer treatment;

7. Palliative radiotherapy is not permitted throughout the study period;

8. Serious non-healing wound, ulcer, or active bone fracture;

9. Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for a major surgical procedure during the course of the study;

10. Refractory nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication;

11. Significant cardiovascular impairment (history of congestive heart failure New York Heart Association [NYHA] Grade >2, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);

12. Active hemoptysis (defined as bright red blood of

13. Current or recent use (within 7 days) of full-dose warfarin (except low-dose warfarin as required to maintain patency of preexisting, permanent indwelling IV catheters). For subjects receiving warfarin, International Normalization Ratio (INR) should be <1.5. Patients may have prophylactic use of low molecular weight heparin, however therapeutic use of heparin or low molecular weight heparin is not acceptable;

14. History of bleeding diathesis or coagulopathy;

15. Any history of cerebral vascular accident, transient ischemic attack or = Grade 2 peripheral vascular disease, unless they have had no evidence of active disease for at least 6 months prior to randomization;

16. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1, unless affected area has been removed surgically;

17. Patients with organ allografts requiring immunosuppression;

18. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or active hepatitis C positive;

19. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, irinotecan, 5-FU, or leucovorin;

20. Hypersensitivity to sulfonamide derivatives; or

21. Have any medical condition that would interfere with the conduct of the study.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• FOLFIRI
FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m^2) and CIV infusion (2400 mg/m^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
• E7820
E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
• Bevacizumab
Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.

Locations

Country	Name	City	State
Australia	Box Hill Hospital	Box Hill	Victoria
Australia	North Coast Cancer Institute	Coffs Harbour	New South Wales
Australia	The Austin Hospital	Epping	Victoria
Australia	Royal Brisbane and Women's Hospital	Herston	Queensland
Australia	Royal Hobart Hospital	Hobart	South Australia
Australia	Sydney Haematology & Oncology Clinic	Hornsby	New South Wales
Australia	Newcastle Private Hospital	Merewether
Australia	Calvary Mater Newcastle	Waratah	New South Wales
Australia	Queen Elizabeth Hospital	Woodville South	South Australia
India	Gujarat Cancer & Research Institute	Ahmedabad
India	Kidwai Institute of Oncology	Bangalore
India	M. S. Ramaiah Memorial Hospital	Bangalore
India	Jawaharlal Nehru Cancer Hospital and Research Centre	Bhopal	Madhya Pradesh
India	Searoc Cancer Hosptial	Jaipur	Rajasthan
India	Subodh Mitra Cancer Hospital and Research centre	Kolkata
India	Shatabdi Hospital	Nashik
India	Deenanath Mangeshkar Hospital and Research Center	Pune
India	Noble Hospital	Pune
India	Christian Medical College	Vellore
Russian Federation	CCH #2 n.a. N. A. Semashko of LLC "Russian Railways"	Moscow
Russian Federation	City Mariinskaya Hospital	St Petersburg
Russian Federation	Scientific Research Oncology Institute named after N.N. Petr	St Petersburg
Russian Federation	Yaroslav Regional Clinical Oncology Hospital	Yaroslav
Ukraine	Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU	Dnipropetrovsk
Ukraine	Donetsk Regional Anticancer Centre	Donetsk
Ukraine	City Clinical Hospital #2	Kharkiv
Ukraine	The St.Inst. "S.P.Grigoriev Med. Rad.Inst. of AMS of Ukr."	Kharkiv
Ukraine	Uzhgorod Centr.City Cl.Hosp.,City Onc.Center, UNMU,Fac.of PG	Uzhgorod
United States	Summit Medical Group	Berkeley Heights	New Jersey
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Rocky Mountain Cancer Center - Midtown	Denver	Colorado
United States	Hematology Oncology Associates SJ P.A.	Mount Holly	New Jersey
United States	Northwest Medical Specialties, PLLC	Tacoma	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Eisai Inc.	Quintiles, Inc.

Countries where clinical trial is conducted

United States,  Australia,  India,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)	Dose-limiting toxicities were defined as clinically significant adverse events (AEs) occurring less than or equal to (<=) 28 days after commencing study treatment and considered by the investigator to be possibly or probably related to study treatment. Toxicity was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v.4.0).	Cycle 1 (each cycle length=28 days)
Primary	Phase 1b: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)	Adverse Events were defined as TEAEs if they started on or after the date and time of administration of the first dose of study drug during the study. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment. Any change in hematology, clinical chemistry, urine values and regular measurement of vital signs which were deemed clinically significant by the investigator were recorded as TEAE.	From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Primary	Phase 1b: Number of Participants With Eastern Cooperative Oncology Group Performance Status (ECOG-PS)	ECOG-PS measured participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than[ >] 50 percent [%] of waking hours), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hours; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead.	From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Primary	Phase 1b: Number of Participants With Clinically Significant Changes in Physical Examinations	Physical examination included examination of the head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, lymph nodes, and neurological status.	From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Primary	Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter	ECG was to be a complete standardized 12-lead recording. The ECGs were reviewed by the investigator or designee prior to study drug administration as part of the participant's standard of care.	From date of first dose up to 30 days after last dose of study treatment (up to 11.5 months)
Secondary	Phase 2: Progression-Free Survival (PFS)	PFS was defined as the time from the date of randomization of a participant to the date of first documentation of PD or death (whichever occurred first) based on investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PD was defined as at least a 20% increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.	From the date of randomization to date of PD or death (whichever occurred first), up to 11 months
Secondary	Phase 2: Time to Progression (TTP)	TTP was defined as time from the date of randomization of a participant until the date of first documented progression of such participant's disease based on investigator assessments according to RECIST v.1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.	From date randomization to date of PD or death, up to 11 months
Secondary	Phase 2: Objective Response Rate (ORR)	ORR was defined as percentage of participants in the study whose best overall response was either CR or PR based on investigator assessments according to RECIST v1.1. A confirmatory scan was required after no less than 4 weeks and no later than 8 weeks, starting on the date that the response was first recorded. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (<)10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	From date of treatment start to until date of first PD or death (whichever occurred first), up to 11 months
Secondary	Phase 2: Overall Survival (OS)	OS was defined as time from the date of randomization of a participant until the date of death of such participant, regardless of the actual cause of the participant's death.	From date of randomization to date of PD or death, up to 11 months